Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Vertex Pharmaceuticals, Inc’s stock clocked out at $444.64, up 1.75% from its previous closing price of $437.01. In other words, the price has increased by $1.75 from its previous closing price. On the day, 1.0 million shares were traded. VRTX stock price reached its highest trading level at $446.28 during the session, while it also had its lowest trading level at $433.81.
Ratios:
To gain a deeper understanding of VRTX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.80. For the most recent quarter (mrq), Quick Ratio is recorded 2.00 and its Current Ratio is at 2.36. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $495.
Leerink Partners Upgraded its Market Perform to Outperform on September 25, 2025, while the target price for the stock was maintained at $456.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’25 when WAGNER CHARLES F JR sold 14,000 shares for $456.00 per share. The transaction valued at 6,384,000 led to the insider holds 37,725 shares of the business.
Tatsis Ourania sold 4,500 shares of VRTX for $2,024,955 on Dec 03 ’25. The EVP, Chief Reg. & Quality Off. now owns 46,793 shares after completing the transaction at $449.99 per share. On Dec 03 ’25, another insider, LEIDEN JEFFREY M, who serves as the Executive Chairman of the company, sold 63,781 shares for $449.20 each. As a result, the insider received 28,650,337 and left with 24,026 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 114001543168 and an Enterprise Value of 108361342976. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.34, and their Forward P/E ratio for the next fiscal year is 21.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.61 while its Price-to-Book (P/B) ratio in mrq is 6.52. Its current Enterprise Value per Revenue stands at 9.243 whereas that against EBITDA is 22.998.
Stock Price History:
The Beta on a monthly basis for VRTX is 0.32, which has changed by -0.0584116 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.68, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 4.81%, while the 200-Day Moving Average is calculated to be 0.55%.
Shares Statistics:
It appears that VRTX traded 1.50M shares on average per day over the past three months and 1347010 shares per day over the past ten days. A total of 253.95M shares are outstanding, with a floating share count of 253.07M. Insiders hold about 0.26% of the company’s shares, while institutions hold 94.64% stake in the company. Shares short for VRTX as of 1764288000 were 4455217 with a Short Ratio of 2.97, compared to 1761868800 on 4131677. Therefore, it implies a Short% of Shares Outstanding of 4455217 and a Short% of Float of 1.9800000000000002.
Earnings Estimates
The market rating for Vertex Pharmaceuticals, Inc (VRTX) is a result of the insights provided by 23.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $4.83, with high estimates of $5.48 and low estimates of $4.29.
Analysts are recommending an EPS of between $19.15 and $17.2 for the fiscal current year, implying an average EPS of $18.45. EPS for the following year is $20.2, with 25.0 analysts recommending between $23.75 and $18.15.
Revenue Estimates
In. The current quarter, 27 analysts expect revenue to total $3.18B. It ranges from a high estimate of $3.35B to a low estimate of $3.1B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.91BFor the next quarter, 27 analysts are estimating revenue of $3.14B. There is a high estimate of $3.27B for the next quarter, whereas the lowest estimate is $2.99B.
A total of 29 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.22B, while the lowest revenue estimate was $11.9B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.05B in the next fiscal year. The high estimate is $14.13B and the low estimate is $12.05B.
